Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study
| dc.contributor.author | Lim, Rachel K. | |
| dc.contributor.author | Tremblay, Alain | |
| dc.contributor.author | Lu, Shengjie | |
| dc.contributor.author | Somayaji, Ranjani | |
| dc.date.accessioned | 2021-12-05T01:03:28Z | |
| dc.date.available | 2021-12-05T01:03:28Z | |
| dc.date.issued | 2021-12-01 | |
| dc.date.updated | 2021-12-05T01:03:28Z | |
| dc.description.abstract | Abstract Background The burden of hospitalizations and mortality for hemoptysis due to bronchiectasis is not well characterized. The primary outcome of our study was to evaluate in-hospital mortality in patients admitted with hemoptysis and bronchiectasis, as well as the rates of bronchial artery embolization, length of stay, and hospitalization costs. Methods The authors queried the Nationwide Inpatient Sample (NIS) claims database for hospitalizations between 2016 and 2017 using the ICD-10-CM codes for hemoptysis and bronchiectasis in the United States. Multivariable regression was used to evaluate predictors of in-hospital mortality, embolization, length of stay, and hospital costs. Results There were 8240 hospitalizations (weighted) for hemoptysis in the United States from 2016 to 2017. The overall in-hospital mortality was 4.5%, but higher in males compared to females. Predictors of in-hospital mortality included undergoing three or more procedures, age, and congestive heart failure. Bronchial artery embolization (BAE) was utilized during 2.1% of hospitalizations and was more frequently used in those with nontuberculous mycobacteria and aspergillus infections, but not pseudomonal infections. The mean length of stay was 6 days and the median hospitalization cost per patient was USD $9,610. Having comorbidities and procedures was significantly associated with increased length of stay and costs. Conclusion Hemoptysis is a frequent indication for hospitalization among the bronchiectasis population. In-hospital death occurred in approximately 4.5% of hospitalizations. The effectiveness of BAE in treating and preventing recurrent hemoptysis from bronchiectasis needs to be explored. | |
| dc.identifier.citation | BMC Pulmonary Medicine. 2021 Dec 01;21(1):392 | |
| dc.identifier.doi | https://doi.org/10.1186/s12890-021-01762-6 | |
| dc.identifier.uri | http://hdl.handle.net/1880/114154 | |
| dc.identifier.uri | https://doi.org/10.11575/PRISM/45438 | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | The Author(s) | |
| dc.title | Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study | |
| dc.type | Journal Article |